Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases

被引:152
作者
Tebbutt, NC
Norman, AR
Cunningham, D
Hill, ME
Tait, D
Oates, J
Livingston, S
Andreyev, J
机构
[1] Royal Marsden Hosp, Dept Med, Gastrointestinal Unit, Sutton SM2 5PT, Surrey, England
[2] Royal Marsden Hosp, Gastrointestinal Unit, London SW3 6JJ, England
关键词
D O I
10.1136/gut.52.4.568
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The role of palliative resection of the primary tumour in patients who present with metastatic colorectal cancer is unclear. Aims: This study compared the incidence of major intestinal complications in such patients who received chemotherapy treatment with or without prior palliative resection of the primary tumour. Patients: The incidence of intestinal obstruction, perforation, fistula formation, and gastrointestinal haemorrhage, and the requirement for abdominal radiotherapy in patients with metastatic colorectal cancer treated at a single institution over a 10 year period was determined. Results: Eighty two patients received initial treatment with chemotherapy without resection of the primary tumour (unresected group) and 280 patients had undergone prior resection (resected group). In the unresected group, the incidence of peritonitis, fistula formation, and intestinal haemorrhage was 2.4% (95% confidence interval (CI) 0.3-8.5%), 3.7% (95% Cl 0.8-10.3%), and 3.7% (95% Cl 0.8-10.3%), respectively, and was not significantly different from the resected group. Intestinal obstruction affected 13.4% (95% Cl 6.9-22.7%) of patients in the unresected group and 13.2% (95% CI 9.2-17.2%) of patients in the resected group. More patients in the unresected group required greater than or equal to3 blood transfusions (14.6% v 7.5%; p=0.048) and abdominal radiotherapy (18.3% v 9.6%; p=0.03) t an the resected group. Conclusions: The incidence of major intestinal complications in patients with unresected colorectal cancer and synchronous metastases who receive initial treatment with chemotherapy is low. Chemotherapy may be successfully used as initial treatment for such patients with no increased risk of most major intestinal complications compared with patients who have undergone initial resection of the primary tumour.
引用
收藏
页码:568 / 573
页数:6
相关论文
共 30 条
  • [1] Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma
    Assersohn, L
    Norman, A
    Cunningham, D
    Benepal, T
    Ross, PJ
    Oates, J
    [J]. BRITISH JOURNAL OF CANCER, 1999, 79 (11-12) : 1800 - 1805
  • [2] PROGNOSTIC FACTORS INFLUENCING SURVIVAL OF PATIENTS WITH ADVANCED COLORECTAL-CANCER - HEPATIC-ARTERY INFUSION VERSUS SYSTEMIC INTRAVENOUS CHEMOTHERAPY FOR LIVER METASTASES
    BEDIKIAN, AY
    CHEN, TT
    MALAHY, MA
    PATT, YZ
    BODEY, GP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (03) : 174 - 180
  • [3] Malignant colorectal obstruction treated by means of self-expanding metallic stents:: Effectiveness before surgery and in palliation
    Camúñez, F
    Echenagusia, A
    Simó, G
    Turégano, F
    Vázquez, J
    Barreiro-Meiro, I
    [J]. RADIOLOGY, 2000, 216 (02) : 492 - 497
  • [4] Cox D. R., 1984, ANAL SURVIVAL DATA
  • [5] Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer
    Crane, CH
    Janjan, NA
    Abbruzzese, JL
    Curley, S
    Vauthey, JN
    Sawaf, HB
    Dubrow, R
    Allen, P
    Ellis, LM
    Hoff, P
    Wolff, RA
    Lenzi, R
    Brown, TD
    Lynch, P
    Cleary, K
    Rich, TA
    Skibber, J
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (01): : 107 - 116
  • [6] Final results of a randomised trial comparing 'Tomudex'(R) (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
    Cunningham, D
    Zalcberg, JR
    Rath, U
    Oliver, I
    vanCutsem, E
    Svensson, C
    Seitz, JF
    Harper, P
    Kerr, D
    PerezManga, G
    [J]. ANNALS OF ONCOLOGY, 1996, 7 (09) : 961 - 965
  • [7] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont, A
    Figer, A
    Seymour, M
    Homerin, M
    Hmissi, A
    Cassidy, J
    Boni, C
    Cortes-Funes, H
    Cervantes, A
    Freyer, G
    Papamichael, D
    Le Bail, N
    Louvet, C
    Hendler, D
    de Braud, F
    Wilson, C
    Morvan, F
    Bonetti, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2938 - 2947
  • [8] Palliative endoscopic therapy of rectal carcinoma
    Dohmoto, M
    Hunerbein, M
    Schlag, PM
    [J]. EUROPEAN JOURNAL OF CANCER, 1996, 32A (01) : 25 - 29
  • [9] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
    Douillard, JY
    Cunningham, D
    Roth, AD
    Navarro, M
    James, RD
    Karasek, P
    Jandik, P
    Iveson, T
    Carmichael, J
    Alakl, M
    Gruia, G
    Awad, L
    Rougier, P
    [J]. LANCET, 2000, 355 (9209) : 1041 - 1047
  • [10] CURATIVE AND PALLIATIVE SURGERY IN ADVANCED CARCINOMA OF LARGE BOWEL
    ELLIS, H
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1971, 3 (5769): : 291 - +